TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05223777

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KINCISE
Description: The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Handheld Mallet
Description: The handheld mallet traditionally used in total hip arthroplasty.
Study: NCT04619979

Intervention type: PROCEDURE
Intervention: patients undergoing gynecological surgery under general anesthesia
Description: patients undergoing gynecological surgery under general anesthesia

Intervention type: PROCEDURE
Intervention: patients undergoing gynecological surgery under general anesthesia
Description: patients undergoing gynecological surgery under general anesthesia
Study: NCT06432153

Intervention type: OTHER
Intervention: observation
Description: Participants who receive routine clinical care, without additional intervention from the study
Study: NCT06084611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provox Life
Description: Compliant use of Provox Life HMEs
Study: NCT05578846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
Study: NCT06023563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality active video gaming using Nintendo switch sports
Description: Playing 2 pre-selected VR active video games from beach tennis, soccer, volleyball, badminton, bowling, and chambara for 10 minutes each with a 5 minute break in-between. Total duration 30-40 minutes.
Study: NCT05578846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
Study: NCT06023563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy balance exercises
Description: Balance exercises: Standing with feet together for 10 seconds 5 times, standing with 1 foot in front of other for 10 seconds 5 times on both sides, standing on one leg for 10 seconds 5 times on both sides, walking with one foot in front of other on a 1-meter-long line for 5 repetitions and standing on a balance board for 30 seconds for 3 repetitions. 5 minutes each of warm-up and cool down exercises. Total duration 20-30 minutes.
Study: NCT05578846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
Study: NCT06585241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273 Variant-containing Formulation
Description: Sterile liquid for injection
Study: NCT06441643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-17043 Ophthalmic Solution
Description: Investigational monotherapy supplied in three concentration levels: low, medium, high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR-17043 Ophthalmic Solution
Description: Investigational monotherapy supplied in three concentration levels: low, medium, high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-17043 Ophthalmic Solution
Description: Investigational monotherapy supplied in three concentration levels: low, medium, high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-17043 Ophthalmic Solution
Description: Investigational monotherapy supplied in three concentration levels: low, medium, high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG043 Ophthalmic Solution
Description: Investigational fixed dose combination supplied in two concentration levels: low and high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG043 Ophthalmic Solution
Description: Investigational fixed dose combination supplied in two concentration levels: low and high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: Marketed monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil 0.02% Ophthalmic Solution
Description: Marketed monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution
Description: Marketed fixed dose combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR-17043 Vehicle
Description: Placebo comparator
Study: NCT04914299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based positive intelligence intervention
Description: A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
Study: NCT05268809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.
Study: NCT03298243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
Study: NCT06408974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: . Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and ,1 mg/kg ketamine added in group A under sterile condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: . Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and iv dexamethasone will be added
Study: NCT05621577

Intervention type: DEVICE
Group type: OTHER
Intervention: MANDIBULAR ADVANCEMENT DEVICE
Description: orthodontically treating obstructive sleep apnea
Study: NCT05655741

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be asked to complete a series of 3 questionnaires that will be used to gain insight into the current expert consensus for Genomic Bereavement care for Pregnancy Loss.~The 2nd and 3rd Questionnaire will be modified from the first to try to generate consensus, depending on the answers from the previous round.
Study: NCT05096195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml
Description: Details described in intervention arm/group description section.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D prophylaxis
Description: Details described in intervention arm/group description section.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring of post-injection calcium and phosphate
Description: Details described in intervention arm/group description section.
Study: NCT05216497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin®, 90 mg capsules
Description: 90-180 mg/day for 7 days on top of standard therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 capsules for 7 days on top of standard therapy
Study: NCT04634071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
Study: NCT05442905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Anesthesia will be induced with propofol 2-3mg/kg
Study: NCT04634071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting nicotine replacement therapy
Description: Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting nicotine replacement therapy
Description: Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting nicotine replacement therapy
Description: Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting nicotine replacement therapy
Description: Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
Study: NCT04634071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity counseling
Description: A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity counseling
Description: A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
Study: NCT05442905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Anesthesia will be induced with propofol 2-3mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Atracurium 0.15mg/kg used for muscle relaxation before intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Atracurium 0.15mg/kg used for muscle relaxation before intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Atracurium 0.15mg/kg used for muscle relaxation before intubation
Study: NCT04634071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity counseling
Description: A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity counseling
Description: A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity counseling
Description: A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity counseling
Description: A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity counseling
Description: A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity counseling
Description: A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity counseling
Description: A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
Study: NCT05442905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane(1%-2%) used during anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane(1%-2%) used during anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane(1%-2%) used during anesthesia
Study: NCT04634071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity counseling
Description: A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity counseling
Description: A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity counseling
Description: A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nicotine replacement therapy
Description: Participants in this group will not receive per required need nicotine replacement therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nicotine replacement therapy
Description: Participants in this group will not receive per required need nicotine replacement therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nicotine replacement therapy
Description: Participants in this group will not receive per required need nicotine replacement therapy.
Study: NCT04821687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ongentys 50mg
Description: Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Madopar Tab. 125 or Perkin Tab. 25-100mg
Description: Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
Study: NCT04634071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nicotine replacement therapy
Description: Participants in this group will not receive per required need nicotine replacement therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nicotine replacement therapy
Description: Participants in this group will not receive per required need nicotine replacement therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nicotine replacement therapy
Description: Participants in this group will not receive per required need nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Products
Description: Participants in this group will receive per required need nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Products
Description: Participants in this group will receive per required need nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Products
Description: Participants in this group will receive per required need nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Products
Description: Participants in this group will receive per required need nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Products
Description: Participants in this group will receive per required need nicotine replacement therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Products
Description: Participants in this group will receive per required need nicotine replacement therapy.
Study: NCT05188222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maltodextrin solution
Description: The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
Study: NCT05740137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AI-assisted colonoscopy
Description: The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
Study: NCT04696484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coopeRATE Prompt
Description: The coopeRATE Prompt intervention is a set of two questions delivered to patients before the clinical encounter that elicit their concerns and goals. The intervention is delivered to patients online, outside the clinic setting.